This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Al-Kuraya, K. Articles by Sauter, G. Search for Related Content PubMed PubMed Citation Articles by Al-Kuraya, K. Articles by Sauter, G.

Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer

¹ King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia; ² Institute of Pathology, Basel University Clinics, Basel, Switzerland; ³ Department of Medical Genetics, Medical University, Sofia, Bulgaria.; ⁴ Institute of Clinical Pathology, Basel, Switzerland; ⁵ Institute of Pathology, City Hospital Triemli, Zürich, Switzerland; ⁶ Praxis Dr. Köchli, Zürich, Switzerland; ⁷ Cantonal Hospital Olten, Olten, Switzerland; ⁸ Frauenklinik Rheinfelden, Rheinfelden, Germany; ⁹ Kreiskrankenhaus Lörrach, Lörrach, Germany; and ¹⁰ Vysis Inc., Downers Grove, Illinois

Multiple different oncogenes have been described previously to be amplified in breast cancer including HER2, EGFR, MYC, CCND1, and MDM2. Gene amplification results in oncogene overexpression but may also serve as an indicator of genomic instability. As such, presence of one or several gene amplifications may have prognostic significance. To assess the prognostic importance of amplifications and coamplifications of HER2, EGFR, MYC, CCND1, and MDM2 in breast cancer, we analyzed a breast cancer tissue microarray containing samples from 2197 cancers with follow-up information. Fluorescence in situ hybridizations revealed amplifications of CCND1 in 20.1%, HER2 in 17.3%, MDM2 in 5.7%, MYC in 5.3%, and EGFR in 0.8% of the tumors. All gene amplifications were significantly associated with high grade. HER2 (P < 0.001) and MYC amplification (P < 0.001) were also linked to shortened survival. In case of HER2, this was independent of grade, pT, and pN categories. MYC amplification was almost 3 times more frequent in medullary cancer (15.9%), than in the histologic subtype with the second highest frequency (ductal; 5.6%; P = 0.0046). HER2 and MYC amplification were associated with estrogen receptor/progesterone receptor negativity (P < 0.001) whereas CCND1 amplification was linked to estrogen receptor/progesterone receptor positivity (P < 0.001). Coamplifications were more prevalent than expected based on the individual frequencies. Coamplifications of one or several other oncogenes occurred in 29.6% of CCND1, 43% of HER2, 55.7% of MDM2, 65% of MYC, and 72.8% of EGFR-amplified cancers. HER2/MYC-coamplified cancers had a worse prognosis than tumors with only one of these amplifications. Furthermore, a gradual decrease of survival was observed with increasing number of amplifications. In conclusion, these data support a major prognostic impact of genomic instability as determined by a broad gene amplification survey in breast cancer.

This article has been cited by other articles:

				G. E Dressing, C. R Hagan, T. P Knutson, A. R Daniel, and C. A Lange Progesterone receptors act as sensors for mitogenic protein kinases in breast cancer models Endocr. Relat. Cancer, June 1, 2009; 16(2): 351 - 361. [Abstract] [Full Text] [PDF]

				J Zustin, K Boddin, M C Tsourlakis, E Burandt, M Mirlacher, F Jaenicke, J Izbicki, W Ruether, J M Rueger, C Bokemeyer, et al. HER-2/neu analysis in breast cancer bone metastases J. Clin. Pathol., June 1, 2009; 62(6): 542 - 546. [Abstract] [Full Text] [PDF]

				Y. Zhang, J. W.M. Martens, J. X. Yu, J. Jiang, A. M. Sieuwerts, M. Smid, J. G.M. Klijn, Y. Wang, and J. A. Foekens Copy Number Alterations that Predict Metastatic Capability of Human Breast Cancer Cancer Res., May 1, 2009; 69(9): 3795 - 3801. [Abstract] [Full Text] [PDF]

				X. Hu, H. M. Stern, L. Ge, C. O'Brien, L. Haydu, C. D. Honchell, P. M. Haverty, B. A. Peters, T. D. Wu, L. C. Amler, et al. Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes Mol. Cancer Res., April 1, 2009; 7(4): 511 - 522. [Abstract] [Full Text] [PDF]

				J.-J. Lee, A. Y M Au, T. Foukakis, M. Barbaro, N. Kiss, R. Clifton-Bligh, J. Staaf, A. Borg, L. Delbridge, B. G Robinson, et al. Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma Endocr. Relat. Cancer, September 1, 2008; 15(3): 801 - 815. [Abstract] [Full Text] [PDF]

				I. Bernard-Pierrot, N. Gruel, N. Stransky, A. Vincent-Salomon, F. Reyal, V. Raynal, C. Vallot, G. Pierron, F. Radvanyi, and O. Delattre Characterization of the Recurrent 8p11-12 Amplicon Identifies PPAPDC1B, a Phosphatase Protein, as a New Therapeutic Target in Breast Cancer Cancer Res., September 1, 2008; 68(17): 7165 - 7175. [Abstract] [Full Text] [PDF]

				L. Melchor and J. Benitez An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes Carcinogenesis, August 1, 2008; 29(8): 1475 - 1482. [Abstract] [Full Text] [PDF]

				A. Fritah, C. Saucier, O. De Wever, M. Bracke, I. Bieche, R. Lidereau, C. Gespach, S. Drouot, G. Redeuilh, and M. Sabbah Role of WISP-2/CCN5 in the Maintenance of a Differentiated and Noninvasive Phenotype in Human Breast Cancer Cells Mol. Cell. Biol., February 1, 2008; 28(3): 1114 - 1123. [Abstract] [Full Text] [PDF]

				J. Adelaide, P. Finetti, I. Bekhouche, L. Repellini, J. Geneix, F. Sircoulomb, E. Charafe-Jauffret, N. Cervera, J. Desplans, D. Parzy, et al. Integrated Profiling of Basal and Luminal Breast Cancers Cancer Res., December 15, 2007; 67(24): 11565 - 11575. [Abstract] [Full Text] [PDF]

				S M. Rodriguez-Pinilla, R. L Jones, M. B K Lambros, E. Arriola, K. Savage, M. James, S. E Pinder, and J. S Reis-Filho MYC amplification in breast cancer: a chromogenic in situ hybridisation study J. Clin. Pathol., September 1, 2007; 60(9): 1017 - 1023. [Abstract] [Full Text] [PDF]

				M. Udler, A.-T. Maia, A. Cebrian, C. Brown, D. Greenberg, M. Shah, C. Caldas, A. Dunning, D. Easton, B. Ponder, et al. Common Germline Genetic Variation in Antioxidant Defense Genes and Survival After Diagnosis of Breast Cancer J. Clin. Oncol., July 20, 2007; 25(21): 3015 - 3023. [Abstract] [Full Text] [PDF]

				M. R. Pochampalli, B. G. Bitler, and J. A. Schroeder Transforming Growth Factor {alpha} Dependent Cancer Progression Is Modulated by Muc1 Cancer Res., July 15, 2007; 67(14): 6591 - 6598. [Abstract] [Full Text] [PDF]

				L. M. Davis, C. Harris, L. Tang, P. Doherty, P. Hraber, Y. Sakai, T. Bocklage, K. Doeden, B. Hall, J. Alsobrook, et al. Amplification Patterns of Three Genomic Regions Predict Distant Recurrence in Breast Carcinoma J. Mol. Diagn., July 1, 2007; 9(3): 327 - 336. [Abstract] [Full Text] [PDF]

				V. Karantza-Wadsworth, S. Patel, O. Kravchuk, G. Chen, R. Mathew, S. Jin, and E. White Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis Genes & Dev., July 1, 2007; 21(13): 1621 - 1635. [Abstract] [Full Text] [PDF]

				S. Y. Kim and W. C. Hahn Cancer genomics: integrating form and function Carcinogenesis, July 1, 2007; 28(7): 1387 - 1392. [Abstract] [Full Text] [PDF]

				Z. Q. Yang, K. L. Streicher, M. E. Ray, J. Abrams, and S. P. Ethier Multiple Interacting Oncogenes on the 8p11-p12 Amplicon in Human Breast Cancer Cancer Res., December 15, 2006; 66(24): 11632 - 11643. [Abstract] [Full Text] [PDF]

				M. Lacroix Significance, detection and markers of disseminated breast cancer cells Endocr. Relat. Cancer, December 1, 2006; 13(4): 1033 - 1067. [Abstract] [Full Text] [PDF]

				J. Hicks, A. Krasnitz, B. Lakshmi, N. E. Navin, M. Riggs, E. Leibu, D. Esposito, J. Alexander, J. Troge, V. Grubor, et al. Novel patterns of genome rearrangement and their association with survival in breast cancer Genome Res., December 1, 2006; 16(12): 1465 - 1479. [Abstract] [Full Text] [PDF]

				J. S. Reis-Filho, P. T. Simpson, N. C. Turner, M. B. Lambros, C. Jones, A. Mackay, A. Grigoriadis, D. Sarrio, K. Savage, T. Dexter, et al. FGFR1 Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas. Clin. Cancer Res., November 15, 2006; 12(22): 6652 - 6662. [Abstract] [Full Text] [PDF]

				K. Wu, A. Li, M. Rao, M. Liu, V. Dailey, Y. Yang, D. Di Vizio, C. Wang, M. P. Lisanti, G. Sauter, et al. DACH1 Is a Cell Fate Determination Factor That Inhibits Cyclin D1 and Breast Tumor Growth. Mol. Cell. Biol., October 1, 2006; 26(19): 7116 - 7129. [Abstract] [Full Text] [PDF]

				C. Ginestier, N. Cervera, P. Finetti, S. Esteyries, B. Esterni, J. Adelaide, L. Xerri, P. Viens, J. Jacquemier, E. Charafe-Jauffret, et al. Prognosis and Gene Expression Profiling of 20q13-Amplified Breast Cancers Clin. Cancer Res., August 1, 2006; 12(15): 4533 - 4544. [Abstract] [Full Text] [PDF]

				M. Lacroix, R.-A. Toillon, and G. Leclercq p53 and breast cancer, an update. Endocr. Relat. Cancer, June 1, 2006; 13(2): 293 - 325. [Abstract] [Full Text] [PDF]

				S Aulmann, N Adler, J Rom, B Helmchen, P Schirmacher, and H P Sinn c-myc Amplifications in primary breast carcinomas and their local recurrences J. Clin. Pathol., April 1, 2006; 59(4): 424 - 4248. [Abstract] [Full Text] [PDF]

				S. P. Linke, T. M. Bremer, C. D. Herold, G. Sauter, and C. Diamond A Multimarker Model to Predict Outcome in Tamoxifen-Treated Breast Cancer Patients Clin. Cancer Res., February 15, 2006; 12(4): 1175 - 1183. [Abstract] [Full Text] [PDF]

				L. Melchor, S. Alvarez, E. Honrado, J. Palacios, A. Barroso, O. Diez, A. Osorio, and J. Benitez The Accumulation of Specific Amplifications Characterizes Two Different Genomic Pathways of Evolution of Familial Breast Tumors Clin. Cancer Res., December 15, 2005; 11(24): 8577 - 8584. [Abstract] [Full Text] [PDF]

				W. J. Howat, A. Warford, J. N. Mitchell, K. F. Clarke, J. S. Conquer, and J. McCafferty Resin Tissue Microarrays: a Universal Format for Immunohistochemistry J. Histochem. Cytochem., October 1, 2005; 53(10): 1189 - 1197. [Abstract] [Full Text] [PDF]

				K. Jirstrom, M. Stendahl, L. Ryden, A. Kronblad, P.-O. Bendahl, O. Stal, G. Landberg, and The South Swedish and Southeast Swedish Breast Can Adverse Effect of Adjuvant Tamoxifen in Premenopausal Breast Cancer with Cyclin D1 Gene Amplification Cancer Res., September 1, 2005; 65(17): 8009 - 8016. [Abstract] [Full Text] [PDF]

				F. Cappuzzo, M. Varella-Garcia, H. Shigematsu, I. Domenichini, S. Bartolini, G. L. Ceresoli, E. Rossi, V. Ludovini, V. Gregorc, L. Toschi, et al. Increased HER2 Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor-Positive Non-Small-Cell Lung Cancer Patients J. Clin. Oncol., August 1, 2005; 23(22): 5007 - 5018. [Abstract] [Full Text] [PDF]

				A. J Butt, C. M McNeil, E. A Musgrove, and R. L Sutherland Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S47 - S59. [Abstract] [Full Text] [PDF]